Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Chronic myelogenous leukemia patient survey shows that side effects are a serious issue

Chronic myelogenous leukemia patient survey shows that side effects are a serious issue

Trial shows safety of pre-transplant expansion of umbilical cord blood stem cells

Trial shows safety of pre-transplant expansion of umbilical cord blood stem cells

New chemotherapy pill shows promise for stubborn lymphomas

New chemotherapy pill shows promise for stubborn lymphomas

Gene therapy used to fight AIDS

Gene therapy used to fight AIDS

Hematopoietic stem cells found to reproduce more slowly than expected

Hematopoietic stem cells found to reproduce more slowly than expected

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Effects of stem cell source and patient age on stem cell transplantation outcomes

Effects of stem cell source and patient age on stem cell transplantation outcomes

Age has no impact on survival after bone marrow transplant

Age has no impact on survival after bone marrow transplant

Novel therapeutic approaches for various forms of thrombocytopenia

Novel therapeutic approaches for various forms of thrombocytopenia

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Dismissed leukemia drug flavopiridol helps chronic lymphocytic leukemia patients

Dismissed leukemia drug flavopiridol helps chronic lymphocytic leukemia patients

Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

Scientists show that endothelial cells give rise to blood stem cells

Scientists show that endothelial cells give rise to blood stem cells

Men who survive childhood leukemia have lower bone mineral density

Men who survive childhood leukemia have lower bone mineral density

FDA accepts Zevalin supplemental biologics license application

FDA accepts Zevalin supplemental biologics license application

Researchers discover genomic causes of acute lymphoblastic leukemia relapse

Researchers discover genomic causes of acute lymphoblastic leukemia relapse

Scientists develop peptide that converts Bcl-2 protein from a cancer cell's friend to a foe

Scientists develop peptide that converts Bcl-2 protein from a cancer cell's friend to a foe

Declines in cancer incidence and death rates across U.S.

Declines in cancer incidence and death rates across U.S.

Discovery of novel drug target for chronic lymphocytic leukemia

Discovery of novel drug target for chronic lymphocytic leukemia

Celator Pharmaceuticals enrols first patient in phase 2 study of CPX-351 in acute myeloid leukemia

Celator Pharmaceuticals enrols first patient in phase 2 study of CPX-351 in acute myeloid leukemia

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.